New cocktail of immune drugs shows promise against tough pancreatic cancer
NCT ID NCT03193190
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 23 times
Summary
This study tested several combinations of immunotherapy drugs in 341 people with pancreatic cancer that had spread to other parts of the body. Participants were split into two groups: those who had not yet received any treatment for their advanced cancer, and those who had already tried one type of chemotherapy. The main goal was to see if these drug combinations could shrink tumors and how safe they were. While not a cure, the approach aims to better control the disease and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Clínica Universidad de Navarra
Pamplona, Navarre, 31008, Spain
-
Columbia University
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Helen Diller Fam Comp Can Ctr
San Francisco, California, 94158, United States
-
Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
Hosp. G. U Gregorio Marañón
Madrid, 28007, Spain
-
Hospital Universitario Ramon y Cajal
Madrid, 28037, Spain
-
Hospital Universitario Vall d Hebron
Barcelona, 08035, Spain
-
Kanagawa Cancer Center
Kanagawa, 241-8515, Japan
-
Lombardi Cancer Center, Georgetown University
Washington D.C., District of Columbia, 20007, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
MorristownMedicalCenter
Morristown, New Jersey, 07962, United States
-
National Cancer Center Hospital
Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
Chiba, 277-8577, Japan
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Smilow Cancer Hospital at Yale New Haven
New Haven, Connecticut, 06510, United States
-
Uni of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
Universitätsklinikum Essen
Essen, 45122, Germany
Conditions
Explore the condition pages connected to this study.